Data / Drug companies / Validus Pharmaceuticals LLC
Validus Pharmaceuticals LLC: 28 products in the FDA NDC directory, labeler code 30698
Validus Pharmaceuticals LLC (labeler code 30698) lists 28 products in the FDA National Drug Code Directory, covering 10 finished drugs by generic name. By type: 28 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on October 1, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 30698
- Products in commercial distribution
- 28
- Packages
- 40
- Finished drugs by generic name
- 10
- Prescription products
- 28
- Over the counter products
- 0
- Flagged as original packager
- 27 of 27 products that carry the flag
- Started marketing in the last 12 months
- 2
- Earliest marketing start
- November 20, 1964
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 28 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 28 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Desipramine hydrochloride | 6 | 8 |
| Metoprolol tartrate | 4 | 46 |
| Carbamazepine | 3 | 52 |
| Benazepril hydrochloride and hydrochlorothiazide | 3 | 7 |
| Benazepril hydrochloride | 3 | 24 |
| Furosemide | 3 | 63 |
| Bumetanide | 3 | 42 |
| Atomoxetine hydrochloride | 1 | 8 |
| Trazodone hydrochloride oral | 1 | 1 |
| Pentoxifylline | 1 | 9 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 15 | 53.6% |
| Tablet, sugar coated | 6 | 21.4% |
| Capsule, extended release | 3 | 10.7% |
| Solution | 3 | 10.7% |
| Tablet, extended release | 1 | 3.6% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Trental | 30698-006 | Tablet, extended release | New drug applications (NDA) | October 1, 2026 |
| Atoncy | 30698-456 | Solution | New drug applications (NDA) | March 20, 2026 |
| Lopressor | 30698-460 | Tablet | New drug applications (NDA) | August 11, 2025 |
| Lopressor | 30698-464 | Solution | New drug applications (NDA) | April 11, 2025 |
| Raldesy tm | 30698-455 | Solution | New drug applications (NDA) | November 26, 2024 |
| Lopressor | 30698-459 | Tablet | New drug applications (NDA) | May 5, 2014 |
| Lopressor | 30698-458 | Tablet | New drug applications (NDA) | May 5, 2014 |
| Equetro | 30698-423 | Capsule, extended release | New drug applications (NDA) | December 10, 2004 |
| Equetro | 30698-421 | Capsule, extended release | New drug applications (NDA) | December 10, 2004 |
| Equetro | 30698-419 | Capsule, extended release | New drug applications (NDA) | December 10, 2004 |
| Lotensin HCT | 30698-454 | Tablet | New drug applications (NDA) | May 30, 1992 |
| Lotensin HCT | 30698-453 | Tablet | New drug applications (NDA) | May 30, 1992 |
| Lotensin HCT | 30698-452 | Tablet | New drug applications (NDA) | May 30, 1992 |
| Lotensin | 30698-450 | Tablet | New drug applications (NDA) | June 21, 1991 |
| Lotensin | 30698-449 | Tablet | New drug applications (NDA) | June 21, 1991 |
| Lotensin | 30698-448 | Tablet | New drug applications (NDA) | June 21, 1991 |
| Bumex | 30698-632 | Tablet | New drug applications (NDA) | February 28, 1983 |
| Bumex | 30698-631 | Tablet | New drug applications (NDA) | February 28, 1983 |
| Bumex | 30698-630 | Tablet | New drug applications (NDA) | February 28, 1983 |
| Lasix | 30698-067 | Tablet | New drug applications (NDA) | April 24, 1978 |
| Lasix | 30698-066 | Tablet | New drug applications (NDA) | April 24, 1978 |
| Lasix | 30698-060 | Tablet | New drug applications (NDA) | April 24, 1978 |
| Norpramin | 30698-021 | Tablet, sugar coated | New drug applications (NDA) | November 20, 1964 |
| Norpramin | 30698-020 | Tablet, sugar coated | New drug applications (NDA) | November 20, 1964 |
| Norpramin | 30698-019 | Tablet, sugar coated | New drug applications (NDA) | November 20, 1964 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.